Is regular review required during Sotorasib treatment?
Sotorasib is a targeted therapy for KRAS G12C mutation-positive non-small cell lung cancer. Due to its strong targeting specificity, it can effectively inhibit tumor growth. However, during the treatment process, patients need to undergo regular review to monitor the efficacy and detect possible adverse reactions in a timely manner to ensure the safety of medication.
First of all, regular imaging examinations are an important part of treatment with sotorasib. Through imaging methods such as CT or MRI, tumor volume changes and treatment response can be evaluated, helping doctors judge the efficacy of drugs and adjust treatment plans in a timely manner. It is generally recommended to conduct imaging review every 6 to 8 weeks, and the frequency can be flexibly adjusted according to the patient's specific conditions.

Secondly, laboratory examinations cannot be ignored. Sotoraxib may cause adverse reactions such as abnormal liver function and hematological toxicity, so liver and kidney function, blood routine and electrolyte levels need to be monitored regularly. By detecting abnormalities in time, doctors can take measures, such as adjusting dosage or giving symptomatic treatment, to avoid serious complications.
In addition, observation of the patient's own symptoms is also critical. If symptoms such as persistent fatigue, jaundice, rash, difficulty breathing, etc. occur during treatment, you should report to the doctor in time and conduct corresponding examinations. Comprehensive imaging, laboratory and clinical performance monitoring can help doctors comprehensively assess the patient's status and ensure the safety and effectiveness of sotoraxib treatment.
To sum up, regular review is indispensable during the treatment with sotoraxib. Standard follow-up can not only evaluate the efficacy, but also detect and deal with side effects early to ensure that patients get the best treatment effect. Patients should strictly follow the doctor's instructions, cooperate with the review, and actively provide feedback on their physical condition to promote smooth treatment.
Reference materials:https://www.lumakras.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)